News

Ansys Reports Robust Growth in Q4 and Full Year 2024 Results

Ansys Reports Robust Growth in Q4 and Full Year 2024 Results

Ansys Financial Highlights for Q4 and FY 2024

Ansys, Inc. (NASDAQ: ANSS) has recently provided key insights into its financial performance for the fourth quarter and full year of 2024. The numbers released indicate a significant upswing in both revenue and earnings, showcasing the company's adeptness in navigating the competitive landscape of simulation software.

Fourth Quarter Results

For the fourth quarter of 2024, Ansys reported a remarkable revenue of $882.2 million. This reflects an impressive increase of 10% in reported currency, translating to a growth of 11% in constant currency, when viewed against its fourth-quarter performance from the previous year. The diluted earnings per share (EPS) stood at $3.21 on a GAAP basis, while it reached $4.44 on a non-GAAP basis, marking a healthy increase from the prior year’s figures.

Operating Performance Metrics

Delving deeper into the operational metrics, Ansys achieved a GAAP operating profit margin of 40.3% and a non-GAAP operating profit margin of 53.3%. The operating cash flows for the quarter reached $258 million, with unlevered cash flows recorded at $266.8 million. The annual contract value (ACV) for the quarter was pegged at $1,094.6 million, an indication of solid demand and customer retention.

Full Year Performance Overview

For the fiscal year ended December 31, 2024, Ansys recorded revenues totaling $2,544.8 million, which translates to a 12% growth in reported currency and 13% growth in constant currency compared to the previous fiscal year. Furthermore, the company’s full-year diluted EPS reached $6.55 on a GAAP basis and $10.91 on a non-GAAP basis, leading to an annual increase in profitability.

Annualized Contract Value and Backlog

The ACV for the entire fiscal year was noted at $2,563 million, with a substantial deferred revenue and backlog amounting to $1,718.3 million as of the end of 2024. This highlights Ansys's healthy financial standing and the robust nature of its business operations.

Regulatory and Market Position

As part of strategic maneuvers, Ansys entered into an agreement with Synopsys, Inc. for acquisition, which has received conditional regulatory clearance in various jurisdictions. The transaction, anticipated to close in the first half of 2025, showcases Ansys’s commitment to growth through partnerships and acquisitions.

Market Expectations and Guidance

Looking forward, Ansys is poised to continue its trajectory of double-digit growth in ACV for FY 2025, indicating not just stability but an expansive future outlook in the simulation software market. The anticipated transaction with Synopsys further enhances Ansys’s potential market footprint and operational capabilities.

Summary

Ansys has demonstrated compelling growth in both Q4 and full-year results for 2024, reinforcing its position as a leader in the simulation market. As the company navigates through the regulatory landscape with its proposed acquisition, stakeholders and investors will be keenly observing Ansys’s performance and strategy in the upcoming year. With strong financial results and an optimistic outlook, Ansys continues to empower innovation across multiple industries.

Frequently Asked Questions

What were Ansys's revenue figures for Q4 2024?

Ansys reported a revenue of $882.2 million for Q4 2024.

How much did the diluted earnings per share increase?

The diluted earnings per share for Q4 2024 increased to $3.21 on a GAAP basis and $4.44 on a non-GAAP basis.

What is the projected growth for FY 2025 ACV?

Ansys expects double-digit growth in Annual Contract Value for FY 2025.

What are the implications of the Synopsys acquisition?

The acquisition by Synopsys is anticipated to enhance Ansys’s market presence and operational efficiencies.

How does the financial performance compare to FY 2023?

The FY 2024 financial metrics indicate a 12% increase in revenue compared to FY 2023, affirming Ansys's growth strategy.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Beverly Hills MD's Dermal Cream Wins Key Beauty Award

Updated Category News Views 2

A Surprise Win in the Beauty World Who doesn't love an underdog story, right? Beverly Hills MD has slid into the limelight with their Dermal Repair Complex snagging the award for 'Beauty Product of the Year.' Talk about sending shockwaves through the beauty industry! Now, these guys might not be a household name yet, but you better believe they've got everyone's attention...

Continue Reading
Curaleaf Expands in Florida Amid Rising Cannabis Demand

Updated Category News Views 1

Curaleaf's Bold Moves in Florida's Ganja Gold Rush Fresh out of the gate, Curaleaf is saddling up for a wild ride into Florida's cannabis frontier. They've just thrown open the doors of their latest dispensary in Riverview, cranking their statewide count up to 77. Now, isn’t that something? If you're tracking these folks, you know that bringing their nationwide total to...

Continue Reading
AI Platform Suno Sued for Exploiting Artists' Identities

Updated Category News Views 1

AI and the Music Business: A Legal Storm Brews Well, it looks like the music world’s hitting a rough patch with AI in the crosshairs. We've got Korein Tillery, a heavyweight in the legal arena, throwing down the gauntlet against Suno, an AI music-generation platform. Folks, welcome to the battleground where art meets tech and identity theft takes a whole new meaning....

Continue Reading
Rackspace Lawsuit Deadline: Investors Must Take Action

Updated Category News Views 2

Rackspace's Legal Predicament: Time for Action Alright folks, if you're holding shares of Rackspace Technology (NASDAQ:RXT), it’s time to sit up and pay attention. This is about more than bad PR or a temporary hiccup in the stock price—this is serious business. We’ve got until September 28, 2026, to decide if we’re in or out on this class action lawsuit train....

Continue Reading
Clinical Trials Services Market Set for Big Growth

Updated Category News Views 0

Eyeing a Market Surge in Clinical Trials Numbers don't lie, and they're painting a promising picture for the clinical trials services market with a solid 8% growth forecasted annually till 2031. From a modest $66.20 billion in 2026, we're looking at ballooning to a hefty $97.41 billion by 2031. What’s cooking? Let me dish it out for you. Key Drivers and Dynamics North...

Continue Reading
Art and Science Blend in Dr. De La Cruz's Approach

Updated Category News Views 2

Redefining Aesthetic Surgery: An Artistic Approach The world of plastic surgery is often seen through the lens of beauty and symmetry, but for Dr. Emmanuel De La Cruz, it's like staring into a whole different universe. This Houston-based plastic surgeon isn't just removing fat—he's reshaping the human canvas with the eye of a sculptor. Beyond the Standard Cut and Snip...

Continue Reading
IVD Study Success: Hybrid Monitoring Boosts Oversight

Updated Category News Views 1

New Strategies for IVD Clinical Studies It's high time we addressed the tangled web of managing in vitro diagnostic (IVD) clinical studies. We're talking about walking a tightrope where sponsors have to juggle regulatory scrutiny, data integrity, and operational efficiency—all while pushing innovation. Simply put, the old ways of doing things just aren't cutting it...

Continue Reading
CAPR Faces Lawsuit and FDA Delay: Investor Alert

Updated Category News Views 1

Trouble Brewin' for Capricor Investors Buckle up, folks. Capricor Therapeutics (NASDAQ: CAPR) is caught in a storm, facing not just the lengthy arm of law with a securities class action, but also a seemingly endless wait with the FDA's decision on their lead product. We're talking serious implications for anyone with skin in the game. The FDA's Delayed Blessing So the...

Continue Reading
Orbis Celebrates 20 Years of Eye Care in Macau

Updated Category News Views 2

Celebrating Two Decades of Eye Health Innovation Orbis, a name synonymous with eye care worldwide, has hit a remarkable milestone. Celebrating two decades of commitment to eye health in Macau, they've rolled out their Flying Eye Hospital with a mission of profound impact. This isn't just about a fancy airplane; it’s about real, lasting change through training projects...

Continue Reading
Faruqi & Faruqi Urge Wix Investors to Act Now

Updated Category News Views 3

Ticking Clock for Wix Investors' Legal Moves The buzz in the stock market is louder than a bull on Wall Street, especially if you're tangled up with Wix.com Ltd. (NASDAQ: WIX). We've got Faruqi & Faruqi, LLP laying down serious advice: move fast or maybe lose your spot in line. The deadline to noodle over your position as a lead plaintiff in their federal securities class...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Take Note: Class Action Affirms MoonLake's Value

Updated Category News Views 139

Class Action Announced for MoonLake Investors Investors in MoonLake Immunotherapeutics, Inc. have recently been alerted to a class action lawsuit initiated by the Portnoy Law Firm. This action is particularly important for those who purchased the company's securities during a specified period. The class action aims to address potential injustices faced by investors who...

Continue Reading
Discover What's Next in Crypto at the VISION Conference

Updated Category News Views 194

U.S. Senator Bernie Moreno Set to Keynote VISION Conference Renowned crypto advocate, U.S. Senator Bernie Moreno, will take the stage as the keynote speaker at the upcoming VISION Crypto Conference founded by Ric Edelman. This event marks its seventh annual gathering, focusing on the evolving landscape of digital assets. The conference promises to bring fresh insights and...

Continue Reading
Calamos Global Total Return Reaches New Heights in Market

Updated Category News Views 35

Calamos Global Total Return Achieves 52-Week High In an impressive display of resilience and growth, Calamos Global Total Return (CGO) stock has soared to a remarkable 52-week high, attaining a price level of $12.17. This achievement signals a significant uptrend for the investment company, showcasing an impressive one-year change with gains of 39.17%. Investor confidence...

Continue Reading
BYD Launches Advanced Battery-Box HVE for Home Energy Needs

Updated Category News Views 308

Introducing BYD Battery-Box HVE Energy Storage System BYD Energy Storage is excited to announce the launch of an innovative energy solution: the BYD Battery-Box HVE. This new system builds on the already successful Battery-Box family, which has gained numerous accolades for its efficiency and reliability in residential energy storage. Outstanding Features of the...

Continue Reading
Exploring Shopify's Stock Performance and Analyst Optimism

Updated Category News Views 227

Shopify's Stock: An Overview of Recent Performance Shopify Inc. has recently become a focal point for investors, particularly as the stock has shown signs of recovery after a drastic decline. The e-commerce platform, renowned for its innovation and growth capabilities, has been navigating the aftermath of its significant drop during the pandemic period. While Shopify once...

Continue Reading